FindTrial
Sign In

Efficacy & Safety of Anticoagulants in Cirrhosis ± HCC

Efficacy and Safety of Anticoagulant Therapy for Portal Vein Thrombosis In Cirrhosis Patients With and Without Hepatocellular Carcinoma

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07132515
Enrollment
100
Registered
2025-08-20
Start date
2023-08-15
Completion date
2025-08-31
Last updated
2025-08-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis, HCC - Hepatocellular Carcinoma, Portal Vein Thrombosis

Brief summary

We will give an anticoagulant against portal vein thrombosis, and watch for the results.

Interventions

DRUGEnoxaparin, warfarrin, or apixaban

Enoxaparin, warfarrin, or apixaban

Sponsors

Mansoura University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Portal vein thrombosis, Cirrhosis, With or without HCC, Child A & B

Exclusion criteria

* Platelets\<10000, Createnine \>1.9, Budd ciarri, Uncontrolled active bleeding

Design outcomes

Primary

MeasureTime frameDescription
Portal vein thrombosis6 monthsdetermine if thrombus resolved or not on anticcoagulant by triphasic CT

Countries

Egypt

Contacts

Primary ContactDalia Elsayed Ganady, MBBS
dalia.tawfik97@gmail.com+201095529264
Backup ContactHatem Elalfy, PhD
elalfy2004@mans.edu.eg+201224790518

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026